Patients with chemorefractory metastatic colorectal cancer derive no overall survival benefit from giving anti-EGFR ...

As a newly christened manufacturing facility comes online in one part of Ireland, Merck KGaA plans to turn out the lights at ...

Among 16 patients with this difficult-to-treat tumor "with few treatment options," the confirmed overall response rate (ORR) ...

Government agreement with IVF drug manufacturer drops price in exchange for tariff reductions, expedited FDA approval ...

Although desmoid tumors do not metastasize, they can be associated with recurrence rates of up to 77% after surgical ...

Median disease-free survival (DFS) increased from 4.8 months with placebo to 9.9 months with adjuvant atezolizumab (Tecentriq ...

EMD Serono also entered an agreement with the U.S. Secretary of Commerce to exclude its pharmaceutical products and ...

President Donald Trump on Friday announced a deal with pharmaceutical company Merck and its U.S. subsidiary, EMD Serono, to ...

Tarlatamab combined with chemoimmunotherapy achieved a 71% objective response rate in ES-SCLC, with a median response duration of 11 months. The safety profile was manageable, with grade 3 or 4 ...

WASHINGTON (AP) — La farmacéutica EMD Serono reducirá el costo de un medicamento común para la fertilidad a través de un acuerdo alcanzado con el gobierno de Estados Unidos, dijo el presidente Donald ...

ITM-11 significantly improved PFS and OS compared to everolimus in GEP-NET patients, meeting primary and secondary endpoints. Subgroup analyses showed ITM-11's efficacy across tumor grades and prior ...